In fact, FLT3 is already used as a treatment biomarker in AML [56,57], and data from cell lines showed that FLT3L CAR-T cells specifically kill FLT3+ leukemia [58]. The gene discussed is FLT3LG; the disease is acute myeloid leukemia.